Raquel Herranz, MSc

PhD Candidate
Hemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, Valencia, Spain

Raquel Herranz, MSc.
Degree in Biotechnology, Master in Biomedical Biotechnology.
Hemostasis, Thrombosis, Ateriosclerosis And Vascular Biology Group, The Health Research Institute Hospital La Fe, Valencia (Spain).
Research stays in Hochschule Bremen and Universität Bremen (Germany) and Trinity College Dublin (Ireland).
Currently researching the utility of liquid biopsy for the identification of patients at high risk of developing urological tumors and cancer-associated thrombosis as part of my PhD.

Presentation(s):

• PB0728 - Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0730 - Circulating activated protein C levels are reduced in cancer patients, a novel contribution to tumorigenesis?

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0731 - Neutrophil activation markers as novel biomarkers for advanced stages of high-grade serous ovarian cancer

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0743 - Cell-free DNA is increased in plasma of immunothrombotically dysregulated patients with periprosthetic joint infection in part due to lower DNaseI activity

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0744 - Coagulation markers improve the diagnosis of periprosthetic joint infection: involvement of immunothrombosis

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB1036 - The increase in plasma cell-free DNA in patients with venous thromboembolism is independent of DNaseI activity

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM